New obesity pill shows promise in early safety trial
NCT ID NCT06942923
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This early-stage study tested a new daily pill, AZD4144, in 28 adults with obesity to see if it is safe and how it affects body inflammation. Participants took either the drug or a placebo for a short time. The main goals were to check for side effects and measure changes in blood markers like IL-6 and CRP, which are linked to inflammation. This research helps understand if the drug might be used in the future to manage obesity-related health issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Berlin, 14050, Germany
Conditions
Explore the condition pages connected to this study.